SALT
LAKE CITY, Oct. 26, 2023 /PRNewswire/ --
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics
company with a unique, patented platform for the development of
molecular diagnostic tests, announced today it will release its
third quarter 2023 results on Thursday,
November 9, 2023, after the market close. The Company will
also host a conference call and webcast on the same day at
4:30 p.m. ET to discuss its financial
results with analysts and institutional investors. Management
on the call will include Dwight
Egan, Chief Executive Officer, Brian
Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
The conference call and webcast will be available via:
Webcast: ir.codiagnostics.com on the
Events & Webcasts page
Conference Call:
844-481-2661 (domestic) or 412-317-0652 (international)
If you are unable to participate during the live webcast, the
call will be recorded and later made available through the
Company's website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc.,
a Utah corporation, is a molecular diagnostics company
that develops, manufactures and markets state-of-the-art
diagnostics technologies. The Company's technologies are utilized
for tests that are designed using the detection and/or analysis of
nucleic acid molecules (DNA or RNA). The Company also uses its
proprietary technology to design specific tests for its Co-Dx PCR
Home™ platform and to locate genetic markers for use in
applications other than infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-third-quarter-2023-earnings-release-date-and-webcast-301968624.html
SOURCE Co-Diagnostics